MLTX

MoonLake Immunotherapeutics

BS score 38.4LOWPHASE3 · mkt cap $1.39B · rev ttm $0

drug hypothesis

Sonelokimab modulates Unknown - not disclosed in provided data to treat Not specified - study is a relative bioequivalence evaluation in healthy adults, not efficacy in patients.

moa:Unknown - not disclosed in provided data

score breakdown

trial design50

base rate disconnect6

language red flags80

composite38.4

valuation analysis

market cap$1.39B

revenue ttm$0

phasePHASE3

historical base rate40%

disconnect ratio0.2x

lead trialNCT06641089

meta

cik0001821586

first discovered2026-04-09

last updated2026-04-10

statusACTIVE

llm model—

extracted at2026-04-10

trial design

Randomized, open-label, single-dose study in 120 healthy adults to evaluate relative bioequivalence of sonelokimab delivered via prefilled syringe versus autoinjector device

primary endpoint:Comparison of pharmacokinetics (PK) of an autoinjector (AI) versus prefilled syringe (PFS) administered single dose of sonelokimab at 64 days

claimed differentiation

Not provided in available data

language red flags

Data provided is extremely limited - only shows a single PK/bioequivalence trial, not a full SEC filing with drug development program details
No information on target, mechanism of action, or therapeutic indication provided
No preclinical evidence or clinical efficacy data included
The 'SEC Filing - Business Section' appears to contain only '6' with no substantive text - likely incomplete submission